Moteur de recherche d’entreprises européennes

Financement de l’UE (17,8 M €) : IMMUnoprofilage intégré de grandes cohortes de patients CANcer adaptatifs Hor01/03/2019 Programme de recherche et d'innovation de l'UE « Horizon »

Vue d’ensemble

Texte

IMMUnoprofilage intégré de grandes cohortes de patients CANcer adaptatifs

IMMUcan proposes an inclusive and integrated European immuno-oncology platform. IMMUcan will access high-quality human biological material (tissue, blood, stool and saliva) and clinical data from patients with colorectal, lung, head & neck, breast, gastric cancers and immune checkpoints inhibitors failures. We have assembled a strong consortium with ten expert clinical centers, access to large volumes of the required tumor types. IMMUcan will mobilize the majority of academic trials running or expected to start recruiting patients during the project period. A centralized workflow for samples, via a state-of-the-art biobank will increase reproducibility as all tissues will be processed and stored in a uniform way, following proofed SOPs. The project will perform in depth immunoprofiling with cutting edge technologies including CyTOFF, single cell RNA-seq, peptidogenomics or microbiome analysis. IMMUcan will analyze the data in order to understand the host/tumour interaction in the absence of treatment (naïve population) and with treatment (patients in follow-up) to identify potential predictive biomarker for response to immunotherapy, or develop rationale for combination therapies. IMMUcan will provide an IT platform and legal/ethical contractual framework where participants from both academia and industry can pursue their own independent investigations utilizing the IMMUcan data and effectively testing and improving the functioning and relevance of the database. A sustainability plan will be developed to ensure the collection of follow-up data and the accessibility of the data platform. The use of the data generating throughout this project, for future research, will be supported.


ABBVIE Inc. 0,00 €
Association Hospitaliere de Bruxelles-Centre Hospitalier Universitaire Jules Bordet 150 000 €
Astrazeneca UK Ltd. 0,00 €
BAYER AG 0,00 €
CELSIUS THERAPEUTICS Inc. 0,00 €
Centre de Lutte Contre le Cancer Leon Berard 200 000 €
CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS 2 042 621 €
CHARITE - UNIVERSITAETSMEDIZIN BERLIN 20 000 €
Cliniques Universitaires Saint-LUC ASBL 30 000 €
Consorcio para La Explotacion del Centro Nacional de Analisis Genomico 115 673 €
De Duve Institute Aisbl 0,00 €
Eli Lilly and Company Ltd. 0,00 €
European Organisation for Research AND Treatment OF Cancer Aisbl 5 825 131 €
Forum des Patients Europeens 210 000 €
Fundacio Centre de Regulacio Genomica 138 268 €
Glaxosmithkline Research & Development Ltd. 0,00 €
Institut Curie 510 000 €
Institut de Recherche Pierre Fabre 0,00 €
Institut de Recherches Internationales Servier 0,00 €
Institut Gustave Roussy 162 500 €
Institut National de la Sante et de la Recherche Medicale 448 320 €
Janssen Pharmaceutica N.V. 0,00 €
Katholieke Universiteit Leuven 1 712 880 €
King's College London 765 066 €
Ligue Nationale Contre le Cancer 40 780 €
Luxembourg Institute OF Health 2 687 841 €
MERCK KGaA 0,00 €
NOVIGENIX SA 0,00 €
Owkin France 0,00 €
Sanofi-Aventis Recherche & Developpement 0,00 €
SIB SWISS INSTITUTE OF BIOINFORMATICS 1 773 000 €
The University of Birmingham 10 000,00 €
UNIVERSITAT ZURICH 728 700 €
Universite Paris Cite 79 220 €
Uniwersytet Warszawski 80 000 €
WEIZMANN INSTITUTE OF SCIENCE 100 000 €

https://cordis.europa.eu/project/id/821558

Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel.